The lancet psychiatry publishes results from advance study evaluating pimavanserin treatment for negative symptoms of schizophrenia

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) announced today that the lancet psychiatry published results from the phase 2 advance study. advance was an international, 26-week, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of adjunctive pimavanserin treatment in outpatients with moderate-to-severe predominant negative symptoms of schizophrenia who had achieved control of positive symptoms with their ongoing antipsychotic treatmen
ACAD Ratings Summary
ACAD Quant Ranking